Triglav Skladi’s Regeneron Pharmaceuticals REGN Stock Holding History

Triglav Skladi’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.32M	Hold	3,000	–	–	0.16%	78
2025 Q4	$2.32M	Hold	3,000	–	–	0.15%	87
2025 Q3	$1.69M	Buy	3,000 +485	+19%	+$274K	0.11%	86
2025 Q2	$1.32M	Buy	+2,515	New	+$1.4M	0.1%	100
2025 Q1	–	Sell	-2,515	Closed	-$1.79M	–	144
2024 Q4	$1.79M	Buy	+2,515	New	+$2.11M	0.14%	78

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Triglav Skladi's REGN Position: Q1 2026 in Review

Triglav Skladi held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 3,000 shares worth $2.32M. The position accounts for 0.16% of the portfolio, ranked #78.

Triglav Skladi first reported a position in REGN in Q4 2024 and has held it in 5 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Triglav Skladi held 3,000 shares of Regeneron Pharmaceuticals worth $2.32M as of Q1 2026.
Triglav Skladi left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
Regeneron Pharmaceuticals made up 0.16% of Triglav Skladi's portfolio in Q1 2026, its #78 holding.
Triglav Skladi first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Triglav Skladi's 13F filing for Q1 2026, filed 4 May 2026.